An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma
A Phase I/II, Open-label Study to Evaluate the Abscopal Response and Safety of Manganese and Standard-of-care Radiotherapy/ SBRT in Subjects With Metastatic Solid Tumors or Lymphoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Weidong Han, M.D.
- Phone Number: +861066937463
- Email: hanwdrsw69@yahoo.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100853
- Recruiting
- Biotherapeutic Department of Chinese PLA General Hospital
-
Contact:
- Weidong D Han, M.D.
- Phone Number: +86-10-66937463
- Email: hanwdrsw69@yahoo.com
-
Sub-Investigator:
- Fengxia Shi
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must have histologically proven metastatic solid tumors or lymphoma.
- Subjects must have at least two distinct measurable sites of disease (≥1 cm).
- ≥ 18 years old.
- Life expectancy of at least 6 months.
- Eastern Cooperative Oncology Group performance status 0-2.
- Subjects must have stable or progressing disease to the ongoing systemic therapy.
- Multiple lines of previous chemo-immunotherapy were permitted.
- Patients with known brain metastases were included in the trial but brain lesions were not eligible as target or non-target lesions.
- Adequate organ function.
- Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug.
- Male participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study drug through 120 days after the last dose of study drug.
Exclusion Criteria:
- Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications.
- Serious uncontrolled medical disorders or active infections, pulmonary infection especially.
- Prior organ allograft.
- Women who are pregnant or breastfeeding.
- Women with a positive pregnancy test on enrollment or prior to investigational product administration.
- Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
- Subjects with previous or concurrent other malignancies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Manganese plus Radiotherapy
Subject received standard-of-care radiotherapy or stereotactic body radiation therapy (SBRT) to one metastatic site.
Manganese inhalation began 1 week after the start of radiotherapy and lasted up to 6 months.
The same systemic therapy before the enrollment will be maintained.
|
Administered by inhalation at 0.4mg/kg/d twice a week
Other Names:
Measurable lesions were targeted for radiotherapy at the discretion of the treating physician.Standard-of-care radiotherapy or SBRT were both allowed.
The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed.
Whether and which should be given depends on the treatment regimen before enrollment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of subjects with an abscopal response
Time Frame: 6 months
|
An abscopal response was defi ned as a decrease in the longest diameter of at least 30% in any measurable (≥1 cm) non-irradiated lesion from baseline.
|
6 months
|
|
Number of subjects with treatment-related adverse events (AEs)
Time Frame: 12 months
|
Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.
AEs were considered to be treatment-related if they had started or worsened within the interval from first study drug administration until the follow-up visit.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease control rate (DCR)
Time Frame: 12 months
|
DCR is defined as the proportion of subjects who achieved a stable disease (SD), partial response (PR) or complete response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
|
12 months
|
|
Overall survival (OS)
Time Frame: 24 months
|
OS time was measured from the study entry to the date of death.
|
24 months
|
|
Progression-free survival (PFS)
Time Frame: 24 months
|
PFS time was measured from study entry to the first documentation of disease progression or death.
Disease progression was determined per the RECIST V1.1.
|
24 months
|
|
Number of participants with laboratory test abnormalities
Time Frame: 12 months
|
The laboratory tests of serum cytokines and chemokines will be performed on day 1 and 3 of each cycle, and the abnormality will be determined by the investigator.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHN-PLAGH-BT-063
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.